subscribe Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Subscribe now
Picture: BLOOMBERG/WALDO SWIEGERS
Picture: BLOOMBERG/WALDO SWIEGERS

Aspen has reported a 15% drop in interim headline earnings per share. The drugmaker says the decline was mainly due to inflationary pressures, supply chain issues and the loss of Covid-19 vaccine sales. Business Day TV caught up with CEO Stephen Saad for more detail on the performance.

Or listen to full audio

Subscribe for free episodes: iono.fm | Apple Podcasts | Spotify | Pocket Casts | Player.fm

Companies in this Story

subscribe Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Subscribe now

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.